Onalespib

Drug Profile

Onalespib

Alternative Names: AT-13387; AT-13387X

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Astex Therapeutics
  • Developer Astex Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Benzamides; Isoindoles; Ketones; Piperazines; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I Malignant melanoma; Solid tumours
  • No development reported Gastrointestinal stromal tumours; Prostate cancer

Most Recent Events

  • 13 Sep 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy) in France (IV) before September 2016
  • 13 Sep 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy) in Spain (IV) before September 2016
  • 13 Sep 2016 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy) in USA (IV) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top